Assess whether the primary endpoint will survive FDA scrutiny (817ca6)

SITUATION A labeling team facing a boxed-warning debate cannot treat an inspector asking for batch records you cannot produce this week as incidental context on complete-response-letter deficiency list. 505(b)(2) development lead must close the primary endpoint will from that extract under Pharma & Life Sciences / CMC and Development Pathways.

DECISION 505(b)(2) development lead in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. Complete-response-letter deficiency list reads as Proceed under protocol once an inspector asking for batch records you cannot produce this week is lined up to the same Pharma & Life Sciences population. 2. Complete-response-letter deficiency list is closer to Pause the pathway after an inspector asking for batch records you cannot produce this week; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in complete-response-letter deficiency list for 505(b)(2) development lead in a labeling team facing a boxed-warning debate. 4. Complete-response-letter deficiency list is missing the fact 505(b)(2) development lead needs after an inspector asking for batch records you cannot produce this week; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether complete-response-letter deficiency list supports the labeled claim 505(b)(2) development lead would keep. 2. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 3. Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move the primary endpoint will for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after an inspector asking for batch records you cannot produce this week, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a labeling team facing a boxed-warning debate.